CN111108203A - 狂犬病病毒抗原构建体 - Google Patents

狂犬病病毒抗原构建体 Download PDF

Info

Publication number
CN111108203A
CN111108203A CN201880060285.4A CN201880060285A CN111108203A CN 111108203 A CN111108203 A CN 111108203A CN 201880060285 A CN201880060285 A CN 201880060285A CN 111108203 A CN111108203 A CN 111108203A
Authority
CN
China
Prior art keywords
hydrocarbon chain
construct
saturated
composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880060285.4A
Other languages
English (en)
Chinese (zh)
Inventor
K.哈希
P.马尔亚拉
M.萨姆萨
O.斯拉克
余东
A.斯托克斯
R.雅拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN111108203A publication Critical patent/CN111108203A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880060285.4A 2017-07-17 2018-07-16 狂犬病病毒抗原构建体 Pending CN111108203A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533312P 2017-07-17 2017-07-17
US62/533312 2017-07-17
PCT/IB2018/055258 WO2019016680A1 (en) 2017-07-17 2018-07-16 ANTIGEN CONSTRUCTS OF LYSSAVIRUS

Publications (1)

Publication Number Publication Date
CN111108203A true CN111108203A (zh) 2020-05-05

Family

ID=63364109

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880060285.4A Pending CN111108203A (zh) 2017-07-17 2018-07-16 狂犬病病毒抗原构建体

Country Status (7)

Country Link
US (2) US11278613B2 (https=)
EP (1) EP3655536A1 (https=)
JP (1) JP2020530765A (https=)
CN (1) CN111108203A (https=)
BR (1) BR112020000802A2 (https=)
CA (1) CA3070042A1 (https=)
WO (1) WO2019016680A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022077330A1 (zh) * 2020-10-15 2022-04-21 中国科学院深圳先进技术研究院 一种新型g基因及其在高效逆向跨单突触中的应用
CN116063410A (zh) * 2022-10-20 2023-05-05 北京标驰泽惠生物科技有限公司 一种狂犬病毒g蛋白的突变体及其应用
WO2023179499A1 (zh) * 2022-03-21 2023-09-28 苏州科锐迈德生物医药科技有限公司 具有甘油骨架的脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110269933A (zh) * 2019-07-17 2019-09-24 苏州世诺生物技术有限公司 一种狂犬病毒亚单位疫苗的制备方法及其应用
CN110643632B (zh) * 2019-09-26 2022-06-10 中国科学院武汉病毒研究所 一种基于甲病毒复制子载体的狂犬病毒感染性克隆及制备方法和应用
WO2022152939A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN113993839B (zh) * 2021-02-05 2024-02-09 嘉晨西海(杭州)生物技术有限公司 一种可离子化脂质分子、其制备方法及其在制备脂质纳米颗粒中的应用
EP4342993A4 (en) * 2021-05-19 2025-05-28 Daiichi Sankyo Company, Limited Hpv infectious disease vaccine
WO2023031858A1 (en) 2021-09-01 2023-03-09 Glaxosmithkline Biologicals Sa Plasmid dna purification methods
WO2023151570A1 (en) * 2022-02-09 2023-08-17 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for rabies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105517569A (zh) * 2013-08-21 2016-04-20 库瑞瓦格股份公司 狂犬病疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4368202A3 (en) 2007-03-30 2024-08-21 The Research Foundation for The State University of New York Attenuated viruses useful for vaccines
EP4019506A1 (en) 2013-12-19 2022-06-29 Novartis AG Lipids and lipid compositions for the delivery of active agents
ES2895651T3 (es) 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
US10125092B2 (en) 2014-09-05 2018-11-13 Novartis Ag Lipids and lipid compositions for the delivery of active agents
CA3045976A1 (en) * 2016-12-09 2018-06-14 Glaxosmithkline Biologicals Sa Chimpanzee adenovirus constructs with lyssavirus antigens
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105517569A (zh) * 2013-08-21 2016-04-20 库瑞瓦格股份公司 狂犬病疫苗

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRITO ET AL.: "A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines", 《MOLECULAR THERAPY》, pages 6 *
BRITO ET AL.: "Self-Amplifying mRNA Vaccines", 《ADVANCES IN GENETICS》, pages 21 - 23 *
SAXENA ET AL.: "A sindbis virus replicon-based DNA vaccine encoding the rabies virus glycoprotein elicits immune responses and complete protection in mice from lethal challenge", 《VACCINE》, pages 6592 - 6601 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022077330A1 (zh) * 2020-10-15 2022-04-21 中国科学院深圳先进技术研究院 一种新型g基因及其在高效逆向跨单突触中的应用
WO2023179499A1 (zh) * 2022-03-21 2023-09-28 苏州科锐迈德生物医药科技有限公司 具有甘油骨架的脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
CN116063410A (zh) * 2022-10-20 2023-05-05 北京标驰泽惠生物科技有限公司 一种狂犬病毒g蛋白的突变体及其应用

Also Published As

Publication number Publication date
JP2020530765A (ja) 2020-10-29
US11278613B2 (en) 2022-03-22
US20220241398A1 (en) 2022-08-04
US20200222526A1 (en) 2020-07-16
EP3655536A1 (en) 2020-05-27
BR112020000802A2 (pt) 2020-07-21
CA3070042A1 (en) 2019-01-24
WO2019016680A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
US20220241398A1 (en) Lyssavirus antigen constructs
US20250064916A1 (en) Immunogenic compositions and uses thereof
CN113194988A (zh) 异源初次免疫加强疫苗组合物及方法
US11780885B2 (en) Zika viral antigen constructs
US20190134184A1 (en) Zika viral antigen constructs
CN116390752A (zh) 自扩增性sars-cov-2rna疫苗
US20230234992A1 (en) Modified betacoronavirus spike proteins
US20240181038A1 (en) Immunogenic compositions
KR20230011369A (ko) mRNA 또는 mRNA 조성물, 및 이의 제조 방법 및 이의 용도
US20240301006A1 (en) Self-amplifying messenger rna
AU2021315795A1 (en) Modified Chikungunya viruses and Sindbis viruses and uses thereof
ES2902787T3 (es) Vacunas de ADNi y procedimientos para utilizar las mismas
US20220023413A1 (en) Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
KR20250140103A (ko) 핵산 및 이의 용도
US11730804B1 (en) Compositions and methods for the prevention and treatment of rabies virus infection
WO2025215618A1 (en) Methods and reagents for treating or preventing ebv

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200505